Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAEST16001 in advanced solid tumors
NCT03159585Phase 1Completed
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Apr 2017
- Primary completion
- Jun 2019
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TAEST16001 in solid tumor, sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Treatment-related adverse events at 28 Days. Started Apr 2017; status: completed.
02
Drugs
TAEST16001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03159585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159585.